Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Transl Med ; 11(2): e295, 2021 02.
Article in English | MEDLINE | ID: mdl-33634976

ABSTRACT

Acute pancreatitis (AP) remains a significant clinical challenge. Mitochondrial dysfunction contributes significantly to the pathogenesis of AP. Milk fat globule EGF factor 8 (MFG-E8) is an opsonizing protein, which has many biological functions via binding to αvß3/5 integrins. Ligand-dependent integrin-FAK activation of STAT3 was reported to be of great importance for maintaining a normal mitochondrial function. However, MFG-E8's role in AP has not been evaluated. METHODS: Blood samples were acquired from 69 healthy controls and 134 AP patients. Serum MFG-E8 levels were measured by ELISA. The relationship between serum concentrations of MFG-E8 and disease severity were analyzed. The role of MFG-E8 was evaluated in experimental models of AP. RESULTS: Serum concentrations of MFG-E8 were lower in AP patients than healthy controls. And serum MFG-E8 concentrations were negatively correlated with disease severity in AP patients. In mice, MFG-E8 administration decreased L-arginine-induced pancreatic injury and mortality. MFG-E8's protective effects in experimental AP were associated with improvement in mitochondrial function and reduction in oxidative stress. MFG-E8 knockout mice suffered more severe pancreatic injury and greater mitochondrial damage after l-arginine administration. Mechanistically, MFG-E8 activated the FAK-STAT3 pathway in AP mice. Cilengitide, a specific αvß3/5 integrin inhibitor, abolished MFG-E8's beneficial effects in AP. PF00562271, a specific FAK inhibitor, blocked MFG-E8-induced STAT3 phosphorylation. APTSTAT3-9R, a specific STAT3 antagonist, also eliminated MFG-E8's beneficial effects under such a condition. CONCLUSIONS: MFG-E8 acts as an endogenous protective mediator in the pathogenesis of AP. MFG-E8 administration protects against AP possibly by restoring mitochondrial function via activation of the integrin-FAK-STAT3 signaling pathway. Targeting the action of MFG-E8 may present a potential therapeutic option for AP.


Subject(s)
Antigens, Surface/blood , Integrins/blood , Milk Proteins/blood , Mitochondria/genetics , Pancreatitis/blood , Pancreatitis/genetics , STAT3 Transcription Factor/blood , Animals , Antigens, Surface/genetics , Disease Models, Animal , Female , Focal Adhesion Kinase 1/blood , Focal Adhesion Kinase 1/genetics , Humans , Integrins/genetics , Male , Mice , Middle Aged , Milk Proteins/genetics , STAT3 Transcription Factor/genetics , Signal Transduction/genetics
2.
Mol Cell Biochem ; 476(5): 1949-1963, 2021 May.
Article in English | MEDLINE | ID: mdl-33507464

ABSTRACT

Focal adhesion kinase (FAK), human myofibrillogenesis regulator-1 (MR-1), ephrin receptor type A4 (EphA4), proto-oncogene tyrosine kinase Src (Src), and protein kinase C (PKC) are important markers in proliferation, survival, and migration in some cancers. However, the significance of each is still unclear in different malignancies, including acute myeloid leukemia (AML). Therefore, this study was conducted to investigate their serum levels in Egyptian adult de novo AML patients (n = 70) against healthy volunteers (n = 20). We managed to study the correlation between each pair and to investigate their association with diagnosis, prognosis, and survival. Serum levels were analyzed using enzyme-linked immunosorbent assay (ELISA). We found that FAK, MR-1, Src, and PKC serum levels were significantly higher in AML patients compared to control (p < 0.0001), and this was associated with significantly lower EphA4 level (p < 0.0001). Interestingly, we also observed a significant negative correlation of FAK (p = 0.027), MR-1 (p = 0.003), Src (p = 0.038), and PKC (p = 0.03) with patients' overall survival (OS) while there was a positive significant correlation between EphA4 and OS (p = 0.007). In conclusion, this study suggests that FAK, MR-1, EphA4, Src, and PKC may be used as early diagnostic and prognostic markers with high sensitivity and specificity in AML patients and thus may be incorporated into the patients' early diagnostic and prognostic panels.


Subject(s)
Focal Adhesion Kinase 1/blood , Leukemia, Myeloid, Acute/enzymology , Leukemia, Myeloid, Acute/mortality , Neoplasm Proteins/blood , Adult , Disease-Free Survival , Female , Follow-Up Studies , Humans , Male , Middle Aged , Proto-Oncogene Mas , Survival Rate
3.
Clin Chim Acta ; 442: 119-24, 2015 Mar 10.
Article in English | MEDLINE | ID: mdl-25623955

ABSTRACT

BACKGROUND: Multiple myeloma (MM) represents a malignancy of B-cells characterized by proliferation of malignant plasma cells in the bone marrow (BM). Versican (VCAN), an extracellular matrix (ECM) protein, appears to be involved in multiple processes in several cancers. Identifying optimum diagnostic markers and delineating its association with disease severity might be important for controlling MM. METHODS: Expression of VCAN and its associated molecules (ß-catenin, ß1 integrin and FAK) were investigated in 60 subjects to evaluate their usefulness as diagnostic marker. Circulatory and molecular levels of above molecules were analyzed in their BM and Blood using ELISA, Q-PCR and western blotting along with their ROC curve analysis. RESULTS: Circulatory levels of VCAN, ß-catenin and FAK were significantly higher in patients with varying significance in each stage. ß-Catenin and FAK intracellular levels were significantly elevated in patients. mRNA levels of all molecules were significantly higher in BMMNCs while VCAN and ß-catenin also showed increase in PBMCs. Upregulation of these molecules was also observed at protein level. ROC curve analysis for VCAN showed absolute combination of sensitivity and specificity for diagnosis in serum. CONCLUSIONS: Significant elevation of VCAN and its associated molecules imply their role in MM. Optimal sensitivity and specificity of VCAN might utilize its importance as potential marker for active disease.


Subject(s)
Biomarkers, Tumor/blood , Biomarkers, Tumor/genetics , Multiple Myeloma/blood , Multiple Myeloma/diagnosis , Versicans/blood , Versicans/genetics , Adult , Aged , Biomarkers, Tumor/metabolism , Female , Focal Adhesion Kinase 1/blood , Focal Adhesion Kinase 1/genetics , Focal Adhesion Kinase 1/metabolism , Gene Expression Regulation, Neoplastic , Humans , Integrin beta1/blood , Integrin beta1/genetics , Integrin beta1/metabolism , Intracellular Space/metabolism , Male , Middle Aged , Multiple Myeloma/genetics , Multiple Myeloma/pathology , RNA, Messenger/genetics , RNA, Messenger/metabolism , ROC Curve , Versicans/metabolism , beta Catenin/blood , beta Catenin/genetics , beta Catenin/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...